WO2001087236A3 - Topical administration of pharmacological compositions for non-systemic treatment of pruritus - Google Patents

Topical administration of pharmacological compositions for non-systemic treatment of pruritus Download PDF

Info

Publication number
WO2001087236A3
WO2001087236A3 PCT/US2001/016100 US0116100W WO0187236A3 WO 2001087236 A3 WO2001087236 A3 WO 2001087236A3 US 0116100 W US0116100 W US 0116100W WO 0187236 A3 WO0187236 A3 WO 0187236A3
Authority
WO
WIPO (PCT)
Prior art keywords
pruritus
topical administration
systemic treatment
pharmacological compositions
skin
Prior art date
Application number
PCT/US2001/016100
Other languages
French (fr)
Other versions
WO2001087236A2 (en
WO2001087236B1 (en
Inventor
Gerald L Klein
Original Assignee
Gerald L Klein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gerald L Klein filed Critical Gerald L Klein
Priority to US10/276,508 priority Critical patent/US20030212078A1/en
Priority to AU2001261746A priority patent/AU2001261746A1/en
Publication of WO2001087236A2 publication Critical patent/WO2001087236A2/en
Publication of WO2001087236A3 publication Critical patent/WO2001087236A3/en
Publication of WO2001087236B1 publication Critical patent/WO2001087236B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Abstract

A pharmacological composition includes an anti-histaminic in spray formulation that reduces symptomatic skin itching of skin without substantially eliciting weight gain or sedation in the patient when the composition is sprayed onto the area of skin at a dosage of at least 10 mg/ml over a period of at least 10 applications. Particularly contemplated anti-histaminic include hydroxyzine and ketotifen.
PCT/US2001/016100 2000-05-17 2001-05-17 Topical administration of pharmacological compositions for non-systemic treatment of pruritus WO2001087236A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/276,508 US20030212078A1 (en) 2001-05-17 2001-05-17 Topical administration of pharmacological compositions for non-systemic treatment of pruritus
AU2001261746A AU2001261746A1 (en) 2000-05-17 2001-05-17 Topical administration of pharmacological compositions for non-systemic treatment of pruritus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20483900P 2000-05-17 2000-05-17
US60/204,839 2000-05-17

Publications (3)

Publication Number Publication Date
WO2001087236A2 WO2001087236A2 (en) 2001-11-22
WO2001087236A3 true WO2001087236A3 (en) 2002-02-28
WO2001087236B1 WO2001087236B1 (en) 2002-03-28

Family

ID=22759661

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/016100 WO2001087236A2 (en) 2000-05-17 2001-05-17 Topical administration of pharmacological compositions for non-systemic treatment of pruritus

Country Status (2)

Country Link
AU (1) AU2001261746A1 (en)
WO (1) WO2001087236A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003212773A (en) 2002-01-04 2003-07-30 Oramon Arzneimittel Gmbh Topical medicine composition of cetirizine and loratadine
EP1327463A1 (en) * 2002-01-04 2003-07-16 Oramon Arzneimittel GmbH Gel comprising Cetirizine and Loratadine for topical application
EP2853262B1 (en) 2009-10-26 2016-11-30 Sephoris Pharmaceuticals, LLC Treatment of sunburn using analgesics and antihistamines
US9566306B2 (en) 2012-04-16 2017-02-14 Zemtsov Enterprises, Llc Formulations and methods for treatment of wounds and inflammatory skin conditions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANN. IMMUNOL. HUNG., vol. 26, no. 2, 1987, pages 601 - 628 *
DATABASE BIOSIS [online] ALCON LAB. INC., (FORT WORTH, TX); YANNI J.M. ET AL.: "Preclinical efficacy of emedastine, a potent, selective histamine H-1 antagonist for topical ocular use", XP002947033, accession no. STN Database accession no. 1995:114356 *
DATABASE BIOSIS [online] DEP. BIOL., SEARLE RES. DEV. (HIGH WYCOMBE, U.K.); TUFFIN D.P. ET AL.: "Immunopharmacology of the guinea-pig conjunctiva", XP002947034, accession no. STN Database accession no. 1987:312024 *
JOURNAL OF OCULAR PHARMACOLOGY, vol. 10, no. 4, 1994, pages 665 - 675 *

Also Published As

Publication number Publication date
WO2001087236A2 (en) 2001-11-22
AU2001261746A1 (en) 2001-11-26
WO2001087236B1 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
WO2004066910A3 (en) Controlled release modifying complex and pharmaceutical compositions thereof
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
WO2002011711A3 (en) Formulations of mometasone and a bronchodilator for pulmonary administration
WO2005046640A3 (en) Multi-site drug delivery platform
WO2003045437A8 (en) Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
CA2370565A1 (en) Dermally applicable vitamin d-containing pharmaceutical compositions
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
WO2004105694A3 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
MY148773A (en) Galenic formulations of organic compounds
AU2001263229A1 (en) Compositions and methods for administration of pharmacologically active compounds
MY129406A (en) Taste masked liquid pharmaceutical compositions
WO2000007979A3 (en) Compounds and compositions for delivering active agents
WO2007022090A3 (en) Topical delivery with a carrier fluid
WO2006058249A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
WO2008023016A3 (en) Galenic formulations of aliskiren
CA2360220A1 (en) Oxadiazole compounds and compositions for delivering active agents
WO2002045686A3 (en) Pharmaceutical paste comprising an acid-labile active ingredient
WO2002015959A3 (en) Compounds and compositions for delivering active agents
CA2494473A1 (en) Stabilized protein compositions for topical administration and methods of making same
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
IL179544A0 (en) Compositions comprising flavonoids and tocotrienols and methods thereof
WO2008062475A3 (en) Pharmaceutical compositions of ursodiol
WO2005082416A3 (en) Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms
RS88404A (en) Low dose liquid entecavir formulation and use
EP2138175A3 (en) Formulations comprising valsartan for treating diabetes or microalbuminuria

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10276508

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP